A Feasibility Study of Adenosine Triphosphate-based Chemotherapy Response Assay (ATP-CRA) as a Chemosensitivity Test for Lung Cancer
2
조회
0
다운로드
7
인용
0
참고문헌
키워드
초록
Purpose: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphatebasedchemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer. Materials and Methods: Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility. Results: The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminated from the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5± 4.6%. The reproducibility of ATP assays was 94±3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies. Conclusion: The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer.
Abstract
Purpose: A chemosensitivity test can reflect the differences in responses of individual cancer patients to chemotherapeutic agents. The adenosine triphosphatebasedchemotherapy response assay (ATP-CRA)is an accurate method, which does not require a large amount of tissue specimen. So far, no studies have evaluated the utility of the ATP-CRA in Korea. Therefore, we investigated the clinical usefulness of the ATP-CRA in 53 patients with lung cancer. Materials and Methods: Tumor tissues were obtained from bronchoscopic biopsies or surgical resections. The validity of ATP-CRA was assessed focusing on the success rate, experimental error level (intraassay mean coefficient of variation [CV]) and reproducibility. Results: The overall success rate of ATP-CRA was 90.6% (48/53). Normal cells were effectively eliminated from the tumor tissues with the use of ficoll gradient centrifugation and immunomagnetic separation, which was confirmed using loss of heterozygosity analysis of the 3p deletion. The mean CV of ATP assays was 10.5± 4.6%. The reproducibility of ATP assays was 94±3.8%. The results of the ATP assays were reported to physicians within 7 days of specimen collection. More than 6 anticancer drugs were tested on the tumor specimens obtained from bronchoscopic biopsies. Conclusion: The ATP-CRA is a stable, accurate and potentially practical chemosensitivity test in patients with lung cancer.
참고문헌 (25)
- "Annual Report of Death StatisticsData in 2003", National Statistics Office.
- "Cisplatin-based adjuvant chemotherapy in patients withcompletely resected non-small-cell lung cancer", 350, pp.351~60 (2004)
- "A randomized trial of adjuvant chemotherapy with uraciltegafurfor adenocarcinoma of the lung", 350, pp.1713~21 (2004)
- "Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs", 298, pp.1321~7 (1978)
- "The ATP assayis more sensitive than the succinate dehydrogenase inhibitiontest for predicting cell viability", 23, pp.273~6 (1987)
- "Comparisonof MTT and ATP-based assays for the measurement of viablecell number", 10, pp.29~34 (1995)
- "Individualizing chemotherapy for solidtumors-is there any alternative", 8, pp.541~8 (1997)
- "Chemosensitivity testing of human tumorsusing a microplate adenosine triphosphate luminescence assay:clinical correlation for cisplatin resistance of ovarian carcinoma", 55, pp.5276~82 (1995)
- "The ex vivo chemosensitivity profile of choroidalmelanoma", 8, pp.756~62 (1997)
- "Heterogeneity of chemosensitivity of metastatic cutaneousmelanoma", 10, pp.437~44 (1999)
- "Intra-arterial mitoxantrone and paclitaxel ina patient with Stewart-Treves syndrome:selection of chemotherapyby an ex vivo ATP-based chemosensitivity assay", 11, pp.269~73 (2000)
- "Individualizedlong-term chemotherapy for recurrent ovarian cancerafter failing high-dose treatment", 13, pp.173~6 (2002)
- "Predictive value of the ATP chemosensitivityassay in epithelial ovarian cancer", 83, pp.334~42 (2001)
- "Correlation of the clinical response tochemotherapy in breast cancer with ex vivo chemosensitivity", 7, pp.630~5 (1996)
- "The usefulnessof the ATP assay with serum-free culture for chemosensitivitytesting of gastrointestinal cancer", 33, pp.960~6 (1997)
- "Outcome of ATP-based tumorchemosensitivity assay directed chemotherapy in heavilypre-treated recurrent ovarian carcinoma", 3, pp.19~ (2003)
- "Correlation of drug response with the ATP tumorchemosensitivityassay in primary FIGO stage III ovariancancer", 77, pp.258~63 (2000)
- "The Reliabilityof histoculture drug response assay (HDRA) in chemosensitivitytest for breast cancer.", 33, pp.392~7 (2001)
- "Principles andpractice of oncology 6th ed.", pp.303~ (2001), Lippincott Williams& Wilkins
- "Review of the efficacy of individualizedchemotherapy selected by in vitro drug sensitivity testingfor patients with cancer", 17, pp.1625~31 (1999)
- "Clinical applicabilityof the ATP cell viability assay as a predictor of chemoresponsein platinum-resistant epithelial ovarian cancer usingnonsurgical tumor cell samples", 76, pp.405~8 (2000)
- "Chemosensitivity testing in oncology", pp.126~45 (2003), Springer-Verlag
- "Chemosensitivity testing with highly purifiedfresh human tumour cells with the MTT colorimetric assay", 7, pp.1258~63 (1991)
- "Tumor tissue is more sensitive to mitomycin C and aclacinomycin A than is adjacent normal tissue in vitro", pp.4~7 (1989)
- "Clinical utilityof adenosine triphosphate-based chemosensitivity response assay(ATP-CRA) in non-small cell lung cancer: preliminarystudy", 23, pp.677~ (2004)